Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab and Obinutuzumab for First-line Treatment of Follicular Lymphoma and Marginal Zone Lymphoma
NCT05783596Phase 2Active, not recruiting
- Start
- Jul 2023
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in follicular lymphoma (FL), marginal zone lymphoma (MZL). Started Jul 2023; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05783596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783596.